This study analyzes 229 MampA and 120 inlicensing deals in the pharmaceutical industry. The author shows from a capital market perspective that MampA experiences significant negative cumulative average abnormal returns whereas inlicensings are able to create value. Significant determinants of success for both strategies are derived.